Determinants and impact of alexithymia on quality of life in Parkinson's disease

被引:3
|
作者
Alvarado-Bolanos, A.
Cervantes-Arriaga, A. [1 ]
Zuazua-Vidal, L. [1 ]
Esquivel-Zapata, O. [1 ]
Alcocer-Salas, A. [1 ]
Rodriguez-Violante, M. [1 ,2 ]
机构
[1] Natl Inst Neurol & Neurosurg, Clin Neurodegenerat Res Unit, Mexico City, Mexico
[2] Natl Inst Neurol & Neurosurg, Movement Disorder Clin, Mexico City, Mexico
来源
NEUROLOGIA | 2023年 / 38卷 / 05期
关键词
Movement disorders; Neuropsychiatry; Affective symptoms; Risk factors; NEUROPSYCHIATRIC SYMPTOMS; COGNITIVE IMPAIRMENT; NONMOTOR SYMPTOMS; SCALE; VALIDATION; DEPRESSION; PREVALENCE; DIMENSIONS; DISORDERS; SEVERITY;
D O I
10.1016/j.nrl.2020.10.012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Alexithymia is a neuropsychiatric symptom conceptualized as difficulty identifying and describing feelings. Although associated with other non-motor symptoms, mainly neuropsychiatric, alexithymia may present as an isolated symptom in persons with Parkinson's Disease (PwP). The objective of the study is to identify determinants of alexithymia and its association with quality of life (QoL) in Parkinson's disease. Methods: Subjects with Parkinson's disease were recruited. The following instruments were applied: Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Non-Motor Symptoms Scale (NMSS), Montreal Cognitive Assessment (MoCA), Toronto alexithymia scale (TAS-20) and Parkinson's Disease Questionnaire (PDQ-8). Matched healthy controls were screened using TAS-20. Clinical and demographical variables were compared between alexithymic and non-alexithymic. Regression models were used to find determinants of alexithymia. Impact of alexithymia on QoL was estimated with a linear regression model. Results: 98 patients were included. 56.1% PwP and 28.8% controls were alexithymic (p < 0.001). Education level (OR 0.86) and NMSS urinary score (OR 1.09) determined alexithymia as well as TAS-20 score. Alexithymia was an independent determinant of QoL. Conclusions: Alexithymia is a prevalent independent non-motor symptom in PwP with impact on QoL. Low education level and urinary symptoms are important determinants of alexithymia. (c) 2020 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数:8
相关论文
共 50 条
  • [21] The impact of subtype and disease duration on quality of life in Parkinson's disease
    Oh, I. J.
    Schiess, M. C.
    Van Horn, G.
    Stimming, E. Furr
    MOVEMENT DISORDERS, 2009, 24 : S369 - S369
  • [22] The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson's Disease
    Pinter, David
    Juhasz, Annamaria
    Harmat, Mark
    Janszky, Jozsef
    Kovacs, Norbert
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson’s Disease
    Dávid Pintér
    Annamária Juhász
    Márk Harmat
    József Janszky
    Norbert Kovács
    Scientific Reports, 10
  • [24] Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease
    Martinez-Martin, Pablo
    Rodriguez-Blazquez, Carmen
    Forjaz, Maria Joao
    Kurtis, Monica M.
    CNS DRUGS, 2015, 29 (05) : 397 - 413
  • [25] Impact of the motor complications of Parkinson's disease on the quality of life
    Chapuis, S
    Ouchchane, L
    Metz, O
    Gerbaud, L
    Durif, F
    MOVEMENT DISORDERS, 2005, 20 (02) : 224 - 230
  • [26] Cognitive profiles in Parkinson's disease and their impact on quality of life
    Glisky, M.
    Olson, K.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2007, 22 (07) : 891 - 891
  • [27] Impact of weight loss on quality of life in Parkinson's disease
    Akbar, U.
    He, Y.
    Wu, S.
    Malaty, I.
    Eilers, A.
    Zamudio, J.
    Schmidt, P.
    Okun, M. S.
    MOVEMENT DISORDERS, 2013, 28 : S107 - S107
  • [28] Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson’s Disease
    Pablo Martinez-Martin
    Carmen Rodriguez-Blazquez
    Maria João Forjaz
    Monica M. Kurtis
    CNS Drugs, 2015, 29 : 397 - 413
  • [29] Fatigue in Patients with Parkinson's Disease: Impact on Quality of Life
    Miwa, Hideto
    Miwa, Takako
    INTERNAL MEDICINE, 2011, 50 (15) : 1553 - 1558
  • [30] Weight Loss and Impact on Quality of Life in Parkinson's Disease
    Akbar, Umer
    He, Ying
    Dai, Yunfeng
    Hack, Nawaz
    Malaty, Irene
    McFarland, Nikolaus R.
    Hess, Christopher
    Schmidt, Peter
    Wu, Samuel
    Okun, Michael S.
    PLOS ONE, 2015, 10 (05):